MAY 8 2026
Genentech — Ocrevus (ocrelizumab) $RHHBY
for relapsing-remitting multiple sclerosis
FDA approved Ocrevus (ocrelizumab) IV infusion for relapsing-remitting multiple sclerosis in pediatric patients aged 10 and older.
About
Multiple sclerosis is an autoimmune disease where the immune system attacks the protective myelin sheath around nerve cells, disrupting signal transmission and causing symptoms like vision loss and muscle weakness. Ocrevus is an antibody that targets and depletes specific B cells of the immune system. By reducing these cells, the drug may lower the immune attack on myelin, potentially reducing disease activity for people with MS.
Pivotal trial
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza vaccine, keyhole limpet hemocyanin \[KLH\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Ocrevus
- Thank you! Ocrevus and Kesimpta will remain on the PBS - MS Australia
- MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS - MS Australia
- Teva & Polpharma strike global deal to bring proposed Ocrevus biosimilar closer to patients worldwide - Indian Pharma Post
- Teva Secures Global Rights to Polpharma's Ocrevus Biosimilar Candidate for Multiple Sclerosis - BioPharm International
- Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar - Yahoo Finance